Li Ka-shing funds Asia’s first non-invasive kidney tumour trials in Hong Kong

AI Summary

The Li Ka Shing Foundation is funding places for 30 patients in Hong Kong’s first Asian clinical trials of histotripsy for kidney tumours. The non-invasive treatment uses focused sound waves to break apart tumours and will be tested at three private hospitals.

Hong Kong will become the first city in Asia to conduct clinical trials of a non-invasive treatment for kidney tumours, with tycoon Li Ka-shing funding places for 30 patients across three private hospitals. The Li Ka Shing Foundation announced on Wednesday that CUHK Medical Centre, Gleneagles Hospital Hong Kong and Hong Kong Sanatorium & Hospital would launch the trials using histotripsy, a technology that uses focused sound waves to break apart tumours without surgical incisions. The trials...